Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study.|https://dx.doi.org/10.1016/j.lana.2025.101193
Anaerobic gut bacteria and their potential role in the initiation, exacerbation, and development of human colorectal cancer: a narrative review.|https://dx.doi.org/10.3389/fcimb.2025.1559001
Haemophagocytic Lymphohistiocytosis: An Uncommon Presentation in Systemic Lupus Erythematosus and Acute Leukaemia.|https://dx.doi.org/10.12890/2025_005555
Irritable bowel syndrome after Clostridioides difficile infection.|https://dx.doi.org/10.15386/mpr-2832
Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis.|https://dx.doi.org/10.1002/cam4.71123
